Madhav Seshadri, MD, BA

Asst Clinical Professor

Medicine Home, Hematology and Oncology UCSF Health

I take care of people with lymphoma and chronic lymphocytic leukemia. I believe in taking an individualized approach to each patient's care. By understanding their values and priorities, together we will arrive at the best treatment plan.

I graduated with honors from Emory University School of Medicine in Atlanta. I completed residency in Internal Medicine and fellowship in Hematology and Oncology at New York Presbyterian Hospital/Weill Cornell Medical Center in New York, where I also served as Chief Fellow. At UCSF I am fortunate to practice at a leading medical center which is at the forefront of cancer care.

Technologies for the diagnosis and treatment of lymphoma and CLL are rapidly evolving, and I will use the latest advancements in providing care for patients. We are also fortunate to have a strong team of specialty consultants, nurse practitioners, nurses, medical technicians, pharmacists, and administrative staff. It would be a privilege to care for you or your family member.

Education
2022 - Chief Fellow, Hematology and Oncology, New York-Presbyterian Hospital, Weill Cornell Medical Center
2022 - Fellowship, Hematology and Oncology, New York-Presbyterian Hospital, Weill Cornell Medical Center
2019 - Residency, Internal Medicine, New York-Presbyterian Hospital, Weill Cornell Medical Center
MD, 2016 - , Emory University School of Medicine
BA, 2009 - Neuroscience, Johns Hopkins University
Honors and Awards
  • Research Training Award for Fellows, American Society of Hematology, 2021-2022
  • Abstract Achievement Award, American Society of Hematology, 2021
  • Ann Hoyt Jolley Merit Scholarship, Emory University School of Medicine, 2015-2016
Publications

  1. Laurence J, Nuovo G, Racine-Brzostek SE, Seshadri M, Elhadad S, Crowson AN, Mulvey JJ, Harp J, Ahamed J, Magro C. Premortem Skin Biopsy Assessing Microthrombi, Interferon Type I Antiviral and Regulatory Proteins, and Complement Deposition Correlates with Coronavirus Disease 2019 Clinical Stage. Volume 192 of Issue 9. The American journal of pathology 2022. PMID: 35640675


  2. Seshadri M, Crane GM, Gergis U. Ofatumumab for Post-Transplant Lymphoproliferative Disorder. Volume 15 of Issue 1. Hematology/oncology and stem cell therapy 2022. PMID: 32413419


  3. Seshadri MR, Melnick AM. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. Volume 63 of Issue 4. Leukemia & lymphoma 2021. PMID: 34783281


  4. Lee EJ, Seshadri M, Bussel JB. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists. Volume 96 of Issue 10. American journal of hematology 2021. PMID: 34152624


  5. Laurence J, Mulvey JJ, Seshadri M, Racanelli A, Harp J, Schenck EJ, Zappetti D, Horn EM, Magro CM. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Volume 219. Clinical immunology (Orlando, Fla.) 2020. PMID: 32771488


  6. Seshadri M, Qu CK. Microenvironmental regulation of hematopoietic stem cells and its implications in leukemogenesis. Volume 23 of Issue 4. Current opinion in hematology 2016. PMID: 27071022


  7. Attaluri A, Seshadri M, Mirpour S, Wabler M, Marinho T, Furqan M, Zhou H, De Paoli S, Gruettner C, Gilson W, DeWeese T, Garcia M, Ivkov R, Liapi E. Image-guided thermal therapy with a dual-contrast magnetic nanoparticle formulation: A feasibility study. Volume 32 of Issue 5. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2016. PMID: 27151045


  8. Song WJ, Seshadri M, Ashraf U, Mdluli T, Mondal P, Keil M, Azevedo M, Kirschner LS, Stratakis CA, Hussain MA. Snapin mediates incretin action and augments glucose-dependent insulin secretion. Volume 13 of Issue 3. Cell metabolism 2011. PMID: 21356520